Y. Xu

First name

Y.

Last name

Xu

Attar-Zadeh, D., Capstick, T., Leese, D., Arnetorp, S., Rapsomaniki, E., Da Costa, K. P., et al. (2023). Healthcare costs associated with short-acting β(2)-agonists in asthma: observational UK SABINA study. Bjgp Open. http://doi.org/10.3399/bjgpo.2023.0015

View

Whittaker, H., Nordon, C., Rubino, A., Morris, T., Xu, Y., de Nigris, E., et al. (2022). Frequency and severity of respiratory infections prior to COPD diagnosis and risk of subsequent postdiagnosis COPD exacerbations and mortality: EXACOS-UK health care data study. Thorax. http://doi.org/10.1136/thorax-2022-219039

View

Whittaker, H., Rubino, A., Mullerova, H., Morris, T., Varghese, P., Xu, Y., et al. (2022). Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. Int J Chron Obstruct Pulmon Dis, 17, 427-437. http://doi.org/10.2147/copd.s346591

View

Hoffman, V., Hallas, J., Linder, M., Margulis, A. V., Suehs, B. T., Arana, A., et al. (2021). Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-021-01095-7

View